Sep 9, 2026 07:30AM
Sep 8, 2026 07:41AM
Aug 13, 2026 04:04PM
Jun 15, 2026 09:15AM
Jun 15, 2026 09:15AM
May 14, 2026 04:02PM
Apr 21, 2026 04:06PM INHIBRX reports interim data on colorectal cancer drug trial
Apr 21, 2026 04:05PM
Apr 20, 2026 05:03PM
Mar 19, 2026 04:00PM
Dec 16, 2025 05:00PM
Dec 16, 2025 05:00PM
Nov 14, 2025 06:00AM
Oct 23, 2025 04:08PM Inhibrx drug meets primary endpoint in rare bone cancer trial
Oct 23, 2025 04:05PM
Oct 22, 2025 04:01PM
Jan 21, 2025 05:01PM
Jan 21, 2025 05:01PM
May 24, 2024 04:01PM
May 24, 2024 04:00PM
May 10, 2024 06:36PM Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
May 8, 2024 04:37PM
Feb 28, 2024 09:15AM
Jan 23, 2024 04:05AM
Jan 23, 2024 01:00AM
Nov 2, 2023 09:22AM
Nov 2, 2023 09:15AM
Sep 19, 2023 04:00PM Inhibrx (INBX) Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the US and Canada
Sep 19, 2023 04:00PM
Aug 7, 2023 04:00PM
May 30, 2023 09:02AM
May 30, 2023 09:00AM
May 15, 2023 06:27AM
May 8, 2023 04:05PM
Apr 26, 2023 09:05AM Inhibrx (INBX) Initiates Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
Apr 26, 2023 09:00AM
Nov 16, 2022 09:01AM
Nov 16, 2022 09:00AM
Nov 7, 2022 04:05PM
Oct 4, 2022 08:01AM
Oct 4, 2022 08:00AM
Oct 3, 2022 04:31PM Inhibrx Inc. (INBX) to Announce Regulatory Pathway for INBRX-101 on October 4th, Before Market Opens
Oct 3, 2022 04:30PM
Aug 23, 2022 07:45AM
Aug 15, 2022 04:06PM
Aug 15, 2022 04:05PM
May 19, 2022 04:05PM
May 16, 2022 09:01AM
May 16, 2022 09:00AM INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing
May 9, 2022 04:05PM

330,725 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All